Form 4: Sage Therapeutics Director Disposes of Options Following Supernus Merger Completion

Sage Therapeutics Director Jessica Federer disposed of 21,500 stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Summary

• Jessica Federer, a Director of Sage Therapeutics, Inc., reported the disposition of 21,500 stock options.
• This transaction occurred on July 31, 2025, which was the effective time of the merger between Sage Therapeutics and Supernus Pharmaceuticals, Inc.
• The stock options, with an exercise price of $6.77 per share, were cancelled and converted into a cash payment and Contingent Value Rights (CVRs) as per the merger agreement.
• The cash payment for these options amounted to $37,195.00, calculated as the difference between the merger's closing amount of $8.50 per share and the option's exercise price ($1.73 per share) multiplied by 21,500 shares.
• In addition to the cash, Ms. Federer received one CVR for each of the 21,500 shares underlying her options.
• Each CVR provides the right to receive up to an additional $3.50 per share in cash upon the satisfaction of specified milestones, as detailed in a Form 8-K filed by Sage Therapeutics on June 16, 2025.
• Options with an exercise price greater than or equal to the $8.50 closing amount were cancelled without any consideration.

Sentiment

Score: 7

Explanation: The filing reports the completion of a pre-announced merger, which is a definitive corporate event. For the director, it represents a realization of value from in-the-money options. The inclusion of CVRs adds a layer of future potential, though also uncertainty. Overall, it's a positive outcome for in-the-money option holders and a planned corporate action.

Positives

• The completion of the merger signifies a successful strategic transaction for Sage Therapeutics, providing a definitive outcome for its shareholders and option holders.
• Option holders with in-the-money options, like Jessica Federer, received a cash payout and Contingent Value Rights (CVRs), providing immediate value and potential future upside.
• The CVRs offer potential additional cash payments of up to $3.50 per share, providing a mechanism for former Sage shareholders to participate in future success based on specific milestones.

Negatives

• The disposition of options marks the end of independent equity ownership for the director in Sage Therapeutics, as the company is no longer a standalone public entity.
• Stock options with an exercise price greater than or equal to the $8.50 closing amount were cancelled without any consideration, resulting in a loss of value for those specific option holders.

Risks

• The full value of the Contingent Value Rights (CVRs) is not guaranteed, as the payment of up to $3.50 per share is contingent upon the satisfaction of specified milestones.
• Future performance of the combined entity under Supernus Pharmaceuticals, Inc. could impact the long-term value for former Sage shareholders who received CVRs, as the achievement of milestones depends on the acquired assets' success.

Future Outlook

The future outlook for former Sage Therapeutics shareholders who received Contingent Value Rights (CVRs) is tied to the achievement of specific milestones by Supernus Pharmaceuticals, Inc., which could result in additional cash payments of up to $3.50 per CVR.

Industry Context

This filing reflects a common trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, innovative firms to expand their pipelines or market share. Mergers often involve a mix of cash and contingent payments, such as CVRs, to bridge valuation gaps and share future risks and rewards associated with pipeline assets.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in a merger is a common mechanism in the pharmaceutical and biotechnology industries, particularly when the acquired company has pipeline assets with uncertain future commercial success.
• Comparable deals often include CVRs tied to regulatory approvals (e.g., FDA approval), commercialization milestones (e.g., first commercial sale, specific sales thresholds), or clinical trial outcomes. For example, the acquisition of MyoKardia by Bristol Myers Squibb included CVRs tied to FDA approval of mavacamten.
• The cash component of $8.50 per share, combined with a potential $3.50 CVR, provides a total potential value of $12.00 per share, which would be evaluated against Sage's pre-merger trading price and analyst price targets to assess the premium offered to shareholders.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (former Sage): Received cash and CVRs for their shares, realizing immediate value and potential future upside.
• Employees (former Sage): Implied impact on employment and compensation structures as Sage integrates into Supernus.
• Management (former Sage): Directors and officers like Jessica Federer had their equity awards converted per merger terms.
• Supernus Pharmaceuticals, Inc.: Acquired Sage Therapeutics, expanding its portfolio and potentially its market presence.

Next Steps

• Monitoring the progress of Supernus Pharmaceuticals, Inc. towards achieving the milestones specified for the Contingent Value Rights (CVRs).
• Former Sage Therapeutics shareholders who received CVRs will await further announcements regarding milestone achievements and potential CVR payouts.

Key Dates

Recommendation

This Form 4 reports the finalization of a pre-announced merger, where Sage Therapeutics became a wholly-owned subsidiary of Supernus Pharmaceuticals. For existing Sage shareholders, the transaction is complete, and they have received their consideration (cash and CVRs). There is no longer a publicly traded Sage Therapeutics stock to buy or sell. For investors considering Supernus, this filing confirms the successful integration of Sage, but a recommendation for Supernus would require a broader analysis of Supernus's financials and strategic outlook, which is beyond the scope of this specific Form 4. Therefore, for Sage, the recommendation is effectively 'hold' as the shares are no longer traded.

Keywords

Sage Therapeutics, Supernus Pharmaceuticals, Merger, Acquisition, Stock Options, Contingent Value Rights, CVR, SEC Form 4, Insider Transaction, Corporate Governance, Biotechnology, Pharmaceuticals